LB-102 for Stable Schizophrenia: Long-Term Safety and Tolerability Study
This study is testing the long-term safety and how well people tolerate a medication called LB-102 for adults with stable schizophrenia. You might be able to join if you are between 18 and 65 years old, have stable schizophrenia, and are currently taking an oral antipsychotic. You also need to be medically stable and have a stable living situation. The main goal is to see how many side effects (adverse events) happen over 52 weeks while taking LB-102. This study is for people who might not be responding well to their current medication, are having side effects, or have finished other LB-102 studies.
- Study design
- This is a Phase 3, open-label (meaning everyone knows what treatment they are receiving), multicenter study planning to enroll about 900 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will evaluate safety and tolerability for 52 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
52-week Open Label Safety-Tolerability Study
At a glance
Conditions
Where it's being run
23 sites across 13 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Evaluate long term safety and tolerability of LB-102 by evaluating the number of adverse event, incidence of treatment emergent events.52 weeks
Overall adverse events, serious adverse events, incidence of treatment emergent events and adverse events which lead to study discontinuation